Josh Jennings
Stock Analyst at Morgan Stanley
(1.60)
# 2,499
Out of 4,667 analysts
14
Total ratings
71.43%
Success rate
9.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $48.05 | +10.30% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $266.58 | +12.54% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $3.32 | +502.41% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $16.78 | +275.45% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.91 | +665.19% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $69.80 | -42.69% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $48.05
Upside: +10.30%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $266.58
Upside: +12.54%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $3.32
Upside: +502.41%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $16.78
Upside: +275.45%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.91
Upside: +665.19%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $69.80
Upside: -42.69%